Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Micafungin

    Client Email Product

    Micafungin

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    32
    US DMFs Filed

    US DMFs Filed

    13
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    5
    Other Certificates

    Other Certificates

    3
    Other Suppliers

    Other Suppliers

    22
    API REF. PRICE (USD / KG)
    133,099

    API Market Place

    8
    INTERMEDIATES
    3
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    24
    Europe

    Europe

    8
    Canada

    Canada

    4
    Australia

    Australia

    0

    South Africa

    South Africa

    2
    Uploaded Dossiers

    Uploaded Dossiers

    9
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    57.00

    Annual Reports

    325.00

    FDF Market Place

    1
    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    16
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    left grey arrow
    right gray arrow
    • INJECTABLE;INTRAVENOUS - EQ 100MG BASE/VIAL
    • INJECTABLE;INTRAVENOUS - EQ 50MG BASE/VIAL
    • SOLUTION;INTRAVENOUS - EQ 100MG BASE/100ML (EQ 1MG BASE/ML)
    • SOLUTION;INTRAVENOUS - EQ 150MG BASE/150ML (EQ 1MG BASE/ML)
    • SOLUTION;INTRAVENOUS - EQ 50MG BASE/50ML (EQ 1MG BASE/ML)
    Full View ScreenFull Screen View
    Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas
    Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas

    https://www.globenewswire.com/news-release/2023/08/28/2732288/0/en/Sandoz-completes-acquisition-of-leading-antifungal-agent-Mycamine-from-Astellas-reinforcing-leading-global-anti-infectives-portfolio.html

    GLOBENEWSWIRE
    28 Aug 2023
    Share Share
    Enforcement Report - Week of February 22, 2023
    Enforcement Report - Week of February 22, 2023

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-22-2023-51785.pdf

    FDA
    22 Feb 2023
    Share Share
    Sandoz signs deal for antifungal from Astellas in buff-up of anti-infectives
    Sandoz signs deal for antifungal from Astellas in buff-up of anti-infectives

    https://endpts.com/sandoz-signs-deal-for-antifungal-from-astellas-in-buff-up-of-anti-infectives-portfolio/

    Paul Schloesser ENDPTS
    25 Jan 2023
    Share Share
    USFDA approves Zydus Lifesciences to market generic Micafungin injection
    USFDA approves Zydus Lifesciences to market generic Micafungin injection

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-approves-zydus-lifesciences-to-market-generic-micafungin-injection/articleshow/95095248.cms

    ECONOMIC TIMES
    25 Oct 2022
    Share Share
    Zydus's Generic Micafungin Sodium Receives Approval in the U.S.
    Zydus's Generic Micafungin Sodium Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215241

    FDA
    24 Oct 2022
    Share Share
    Nanjing's Generic Micafungin Sodium Receives Approval in the U.S.
    Nanjing's Generic Micafungin Sodium Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215381

    FDA
    28 Sep 2022
    Share Share
    Enforcement Report - Week of September 1, 2021
    Enforcement Report - Week of September 1, 2021

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-1-2021-1630499458.pdf

    FDA
    01 Sep 2021
    Share Share
    Xellia Pharms Aps's Generic Micafungin Sodium Receives Approval In US
    Xellia Pharms Aps's Generic Micafungin Sodium Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211713

    FDA
    02 Jun 2021
    Share Share
    U.S. FDA Approves sNDA for Expanded Indication of MYCAMINE
    U.S. FDA Approves sNDA for Expanded Indication of MYCAMINE

    https://www.prnewswire.com/news-releases/us-fda-approves-supplemental-new-drug-application-snda-for-expanded-indication-of-mycamine-micafungin-for-injection-for-the-treatment-of-invasive-candidiasis-in-pediatric-patients-less-than-4-months-of-age-300983804.html

    PR NEWSWIRE
    08 Jan 2020
    Share Share
    U.S. FDA Approves sNDA for Expanded Indication of MYCAMINE
    U.S. FDA Approves sNDA for Expanded Indication of MYCAMINE

    https://www.prnewswire.com/news-releases/us-fda-approves-supplemental-new-drug-application-snda-for-expanded-indication-of-mycamine-micafungin-for-injection-for-the-treatment-of-invasive-candidiasis-in-pediatric-patients-less-than-4-months-of-age-300983804.html

    PR NEWSWIRE
    07 Jan 2020
    Share Share
    U.S. FDA Approves sNDA for Expanded Indication of MYCAMINE
    U.S. FDA Approves sNDA for Expanded Indication of MYCAMINE

    https://www.prnewswire.com/news-releases/us-fda-approves-supplemental-new-drug-application-snda-for-expanded-indication-of-mycamine-micafungin-for-injection-for-the-treatment-of-invasive-candidiasis-in-pediatric-patients-less-than-4-months-of-age-300983804.html

    PR NEWSWIRE
    07 Jan 2020
    Share Share
    Fresenius Kabi`s Generic Micafungin Sodium Receives Approval in US
    Fresenius Kabi`s Generic Micafungin Sodium Receives Approval in US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207344

    FDA
    22 May 2019
    Share Share
    Mycamine® (micafungin sodium): Astellas Pharma vs. Xellia Pharmaceuticals
    Mycamine® (micafungin sodium): Astellas Pharma vs. Xellia Pharmaceuticals

    https://insight.rpxcorp.com/litigation_documents/13146112

    PATENT LITIGATION
    24 Nov 2018
    Share Share
    Apotex’s Generic Micafungin Receives Tentative Approval In US
    Apotex’s Generic Micafungin Receives Tentative Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208366

    FDA
    25 Apr 2018
    Share Share
    Enforcement Report - Week of February 14, 2018
    Enforcement Report - Week of February 14, 2018

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-14-2018-1518587433.pdf

    FDA
    14 Feb 2018
    Share Share
    Zhejiang Hisun Pharmaceutical, Co., Ltd. (Yantou Campus) Fails EDQM Inspection
    Zhejiang Hisun Pharmaceutical, Co., Ltd. (Yantou Campus) Fails EDQM Inspection

    https://www.pharmacompass.com/pdf/news/zhejiang-hisun-pharmaceutical-co-ltd-yantou-campus-fails-edqm-inspection-1483966941.pdf

    EDQM
    19 Sep 2016
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search